Maxim downgraded Matinas BioPharma (MTNB) to Hold from Buy. The company announced that partnering negotiations for its lead asset MAT2203 – oral amphotericin – as part of the previously disclosed non-binding term sheet regarding global rights were terminated by the prospective partner, and as a result, Matinas is implementing 80% workforce reduction, the analyst tells investors in a research note. The company had $14.3M in cash at the end of Q2, which should provide operating capital into 2025, but it also lacks funds to materially advance any programs forward, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTNB:
- Matinas BioPharma downgraded to Hold from Buy at Maxim
- Matinas BioPharma says MAT2203 partnership negotiations terminated
- Matinas BioPharma Slashes Workforce Amid Financial Turmoil
- Biotech Alert: Searches spiking for these stocks today
- Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested